Michael Broder, MD, MSHS, President of PHAR, along with Jesse Ortendahl, Director of Health Economics at PHAR, recently spoke at Evidence Matters ’21, a virtual summit for the literature review community. At the meeting, they joined Dr. Patti Peeples of HealthEconomics.com in a session titled “Applying Systematic Reviews to Real-World Evidence Study Design.” The session highlighted how the increase in publications using real-world data impacts systematic literature reviews, along with the use of real-world evidence in other areas such as economic modeling.
Presentations & Events
Research conducted by PHAR and supported by Amgen was presented in the poster sessions at AMCP Nexus in Denver, CO. PHAR’s claims analysis on psoriatic arthritis (PsA) patients compared biologic initiation risk in systematic-naïve PsA adult patients using apremilast versus methotrexate, building on research previously presented at AMCP 2021 and AAD VMX. The investigators’ findings suggest that patients who initiate apremilast are more adherent and have a lower likelihood of biologic initiation when compared with patients initiating methotrexate. In patients who do need biologics, time to biologic initiation is longer in apremilast users than in methotrexate users. The poster can be viewed on PHAR’s publications page and the abstract was published in the October supplement issue of AMCP’s Journal of Managed Care & Specialty Pharmacy (JMCP).
Two studies conducted by PHAR were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The first study, done in partnership with Sanofi US, examined the effectiveness of teriflunomide in patients with relapsing multiple sclerosis (RMS) who switched from other DMTs following disease progression. The authors of this retrospective chart review study observed that RMS patients who switched to teriflunomide after progression may have experienced reductions in EDSS scores and stable or reduced relapse rates. In the second study, PHAR collaborated with Genentech to develop a claims-based algorithm to identify patients with neuromyelitis optica spectrum disorder (NMOSD) and distinguish them from patients with multiple sclerosis and other central nervous system inflammatory disorders, allowing researchers and clinicians to better estimate NMOSD burden. The posters can be viewed on the PHAR website publications page and the abstracts were published in the October supplement issue of Multiple Sclerosis Journal.
PHAR’s President Michael S. Broder, MD, MSHS, and Director of Health Economics, Jesse Ortendahl, appeared at a roundtable hosted by Evidence Partners and HealthEconomics.com to address questions around how to best automate systematic reviews. With the increasing number of scientific journals over the last few years, using the most effective and up-to-date methods for conducting literature reviews has become a must. Michael and Jesse shared best practices learned conducting systematic reviews over two decades. The pair will also be presenting at EP’s upcoming Evidence Matters ’21.
PHAR’s Sheila Reiss Reddy, PhD, RPh, Eunice Chang, PhD, and Marian Tarbox, MPP worked with collaborators at Akcea Therapeutics, Inc., to conduct a retrospective analysis using Medicare claims data to identify cardiovascular conditions within 3 years prior to a transthyretin amyloidosis (ATTR) diagnosis. Findings show Medicare beneficiaries with ATTR have considerable cardiovascular conditions prior to diagnosis. Awareness of characteristic cardiovascular symptoms could lead to earlier diagnosis and prompt intervention. Results were presented as a poster at the virtual Heart Failure Congress 2021, and can be viewed here.
PHAR’s Sheila Reiss Reddy, PhD, RPh, Eunice Chang, PhD, and Marian Tarbox, MPP, in collaboration with investigators at Akcea Therapeutics, Inc., presented at the American Association of Heart Failure Nurses 17th Annual Meeting. The study found that patients diagnosed with hereditary transthyretin amyloidosis (ATTRv [variant]) have considerable cardiovascular disease burden in the 5 years preceding diagnosis. Heart failure nurses’ recognition of ATTRv cardiovascular manifestations may increase clinical suspicion, leading to earlier diagnosis. The poster can be found here, and the abstract published in Heart & Lung‘s July/August 2021 issue.
Alongside PHAR’s first virtual exhibit presence at Virtual ISPOR 2021, PHAR investigators presented their findings outlining the national burden of achondroplasia in adults and children, done in conjunction with BioMarin Pharmaceutical. Their examination of the National Inpatient Sample, the largest all-payer inpatient healthcare database in the US, provided the first national estimate of the cost or burden of hospitalization and surgery in adults and children with achondroplasia. They estimated that the annual cost of hospitalization alone was $40 million. The iPoster can be viewed here, and the abstract was published in the May 2021 supplement issue of Value in Health.
PHAR’s Sheila Reiss Reddy, PhD, RPh, Eunice Chang, PhD, and Marian Tarbox, MPP, in collaboration with investigators at Akcea Therapeutics, Inc., conducted two studies investigating cardiovascular complications associated with transthyretin-mediated (ATTR) amyloidosis. Their first study analyzed a large US insurance claims database to identify patients with ATTR amyloidosis and cardiomyopathy (ATTR-CM) and to estimate the US prevalence and incidence of ATTR-CM. Their second study examined cardiovascular symptom manifestation and healthcare use leading up to an ATTR diagnosis among Medicare beneficiaries in the US. Their findings were presented as posters at American College of Cardiology’s 70th Annual Scientific Session & Expo and can be found on the PHAR publications page, and published as abstracts in the Journal of the American College of Cardiology‘s May 2021 supplement issue.
PHAR is proud to announce their sponsorship at Virtual ISPOR 2021 and will be hosting a virtual exhibit at the meeting. Registered attendees will be able to learn more about PHAR’s research and services and chat live with President Michael S. Broder, MD, MSHS, and Vice President, Mallik Greene, BPharm, PhD, DBA.
PHAR presented research on transthyretin-mediated (ATTR) amyloidosis and Huntington’s disease (HD) at the virtual 2021 Annual Meeting of the American Academy of Neurology. PHAR’s Sheila Reiss Reddy, PhD, RPh, Eunice Chang, PhD, and Marian Tarbox, MPP, in partnership with Akcea Therapeutics, Inc., investigated the feasibility of estimating ATTR amyloidosis prevalence and incidence using IBM® MarketScan® Commercial and Medicare databases. They also presented research on the clinical characteristics and resource use patterns among Medicare beneficiaries with ATTR amyloidosis in the years before diagnosis. In addition, PHAR’s Sheila Reiss Reddy, PhD, RPh, and Eunice Chang, PhD, in partnership with Genentech, Inc., presented their findings on healthcare resource use among US Medicare beneficiaries with late-onset HD. The posters for these studies can be found on the PHAR publications page, and the abstracts were published in Neurology’s April 2021 supplement issue.